Castle Biosciences, Inc.
NASDAQ:CSTLMedical - Diagnostics & Research
+$0.04 today
- Market cap
- $1.03B
- Beta
- 1.02
- P/E (TTM)
- -47.3
- EPS (TTM)
- -$0.43
Volume 0.38M
Average 0.37M
CSTL Other Financing Activities
Financing cash flows not reported separately.
Castle Biosciences, Inc.NASDAQ: CSTL
Other Financing Activities · Q1 FY2026 · quarter ended Mar 2026
Other financing activities growth accelerates
Q1 FY2026 other financing activities of $5.33M (cash outflow) rose 245.0% year over year, ahead of the +101.4% change in trailing-twelve-month other financing activities. Sequentially, it fell 19.9% from the prior quarter.
Context
- Other financing activities amounted to 2.6% of revenue in FY2025, up 0.9 pp from a year earlier.
- Other financing activities increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +245.0% holds above the trailing-twelve-month pace of +101.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Other Financing Activities history
USD · from the cash flow
- Latest · FY2025
- (9.05M) USD
- Year-over-year change
- -56.6%
| Period | Period end | Other Financing Activities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (9.05M) | -56.6% |
| FY2024 | 2024-12-31 | (5.78M) | -168.1% |
| FY2023 | 2023-12-31 | (2.16M) | -231.7% |
| FY2022 | 2022-12-31 | 1.64M | -69.8% |
| FY2021 | 2021-12-31 | 5.43M | — |
Other Financing Activities vs competitors
How CSTL compares with its peers on the latest reported figures
- CSTL's LTM Mar 2026 other financing activities of $12.81M is the 4th largest of the 8 companies compared; the peer median is $8.58M.
- Its year-over-year change of +101.4% is the 5th highest of 7, against a peer median of +574.5%.
- Other financing activities amounts to 3.8% of revenue for CSTL, versus a peer median of 2.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $282.06M | +866.3% | -30.2% | 22.1% | |
| LTM Mar 2026 | $17.6M | +282.6% | +23.3% | 2.1% | |
| LTM Jun 2026 | $15.84M | +1146.0% | — | 2.8% | |
| LTM Mar 2026 | $12.81M | +101.4% | — | 3.8% | |
| FY2025 | $8.91M | +15.3% | +84.8% | 8.3% | |
| LTM Jun 2026 | $8.58M | — | — | 1.1% | |
| LTM Mar 2026 | $1.33M | +5228.0% | -56.8% | 1.4% | |
| LTM Mar 2026 | $589K | -96.7% | — | 0.9% | |
FRNMFreenome, Inc. Common stock | — | — | — | — | — |
| Peer median (excluding CSTL) | $8.58M | +574.5% | -3.5% | 2.1% | |
Competitors are the stored peer set for CSTL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (31.29M) | (67.14M) | (57.47M) | 18.25M | (24.16M) |
| Depreciation & Amortization | 3.41M | 10.54M | 12.33M | 16M | 40.77M |
| Deferred Income Tax | (8.74M) | (1.88M) | (223K) | 1.4M | (6.23M) |
| Stock-Based Compensation | 21.74M | 36.32M | 51.22M | 50.32M | 45.89M |
| Change in Working Capital | (4.1M) | (7K) | (6.63M) | (14.13M) | 13.6M |
| Accounts Receivables | (4.63M) | (6.22M) | (14.93M) | (12.64M) | 6.88M |
| Inventory | 327K | (1.68M) | (3.96M) | (193K) | (2.14M) |
| Accounts Payables | (182K) | 582K | 5.71M | (4.37M) | 3.08M |
| Other Working Capital | 384K | 7.31M | 6.56M | 3.08M | 5.79M |
| Other Non-Cash Items | 0 | (19.5M) | (4.86M) | (6.97M) | (5.53M) |
| Operating Cash Flow | (18.98M) | (41.66M) | (5.63M) | 64.87M | 64.35M |
| Capital Expenditures | (3.48M) | (5.63M) | (13.62M) | (28.33M) | (36.02M) |
| Acquisitions (Net) | (63.18M) | (26.97M) | 0 | 18K | (18.73M) |
| Purchases of Investments | 0 | (134.69M) | (189.08M) | (205.73M) | (188.71M) |
| Sales of Investments | 0 | 0 | 186.5M | 183.9M | 190.73M |
| Other Investing Activities | 10K | 742K | 13K | 0 | (7.64M) |
| Investing Cash Flow | (66.66M) | (166.55M) | (16.18M) | (50.14M) | (60.37M) |
| Debt Repayment | (8K) | (122K) | (142K) | 9.9M | (115K) |
| Common Stock Issued | 0 | 0 | 0 | 2.02M | 2.21M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 5.43M | 1.64M | (2.16M) | (5.78M) | (9.05M) |
| Financing Cash Flow | 5.42M | 1.52M | (2.3M) | 6.14M | (6.96M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (80.22M) | (206.69M) | (24.11M) | 20.87M | (2.98M) |
| Free Cash Flow | (22.47M) | (47.29M) | (19.25M) | 36.54M | 28.33M |
Castle Biosciences, Inc.
NASDAQ:CSTL
Intrinsic Alpha fair value
Locked
Current Price
$33.38
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.